Melanoma

IRB#11848
Phase III
Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

IRB#15661
A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

IRB#16125
A Phase 1b/2, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of SD-101 with Pembrolizumab in Patients with Metastatic Melanoma

IRB#16198
A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

IRB#11313
A Phase II Study of Iplimumab and HF10 for Stage IIIIB/C, or IV Unresected or Metastatic Malignant Melanoma

IRB#15298 Randomized Phase III trial of Dabrafenib + Trametinib followed by Iplimumab + Nivolumab at Progression vs. Iplimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

Uveal Melanoma

IRB#16162
A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

Adjuvant Therapies

Stages 2B, 2C, or 3

Stages 3 or 4 resectable

New study coming soon

Stages 3 or 4, unresectable

Non-Mutation Specific

Mutation Specific

BRAF V600 Mutation

http://www.ohsu.edu/research/rda/so/knight.php

2/6/17